



**Scale Biosciences Announces Presentations at Upcoming Scientific Conferences**  
*Company to share data on its combinatorial indexing technology at American Society of Human Genetics and Society for Neuroscience annual meetings*

SAN DIEGO, CALIF.- November 2, 2023 - Scale Biosciences (ScaleBio), an innovator in single cell sequencing leveraging combinatorial indexing technologies, today announced upcoming customer presentations and product data releases at the American Society of Human Genetics (ASHG) and Society for Neuroscience (SfN) annual meetings, both being held in Washington, D.C. The presentations will highlight data from research completed by ScaleBio scientists and customer collaborators.

The presentations include:

**American Society for Human Genetics Annual Meeting**

**Presentation Title:** Enhanced single cell DNA methylation analysis using combinatorial sequencing

**Presenter:** Sanika Khare, Applications Scientist, ScaleBio

**Presentation Details:** Thursday, November 2, 3:45-4:15 p.m. Eastern, CoLab Theater 3

**Poster Board #:** PB2260

**Poster Presentation Details:** Saturday, November 4, 2:15 – 4:15 p.m., Exhibit Poster Hall A/B  
In this study, ScaleBio's single-cell methylation kit was used to investigate DNA methylation patterns during development and oncogenesis in brain cells and cancer cells, particularly IDH mutant glioma cells. Mutations in IDH genes affect DNA methylation patterns, prevalent in over 80% of high-grade gliomas. Analyzing single cell methylomes from brain tissues and glioma cells revealed unique methylation profiles, emphasizing the platform's enhanced sensitivity, specificity, and accuracy compared to prior techniques. This comprehensive approach sheds light on altered epigenetic landscapes, providing profound insights into cellular heterogeneity and regulatory mechanisms at high resolution.

**Society for Neuroscience Annual Meeting**

**Presentation Title:** Investigating epigenetic gene regulation and cell fate determination in the MYT1L autism model

**Presenters:** Jason Koth, Senior Product Manager, ScaleBio and Allen Yen, Ph.D. candidate, Washington University of St. Louis

**Presentation Details:** Sunday, November 12, 10 a.m. Eastern, Product Theater

MYT1L is hypothesized to transcriptionally regulate neuronal maturation, however, this has been difficult to test directly. Single cell genomics was used to study MYT1L's influence on the timing of transcriptional maturation and specification across cortical cell types. Using these tools, deep layer neurons were identified as the most sensitive to loss of MYT1L and exhibited altered developmental trajectories, failing to reach a terminal mature state. This research

highlights MYT1L's role as a transcriptional regulator and provides insight into cell type-specific mechanisms for future targeted studies.

For more information, visit ScaleBio at ASHG at booth #1107 or at SfN at booth #827 or visit <https://scale.bio/events/>.

### **About Scale Biosciences**

ScaleBio is a single cell sequencing solutions company founded by a multidisciplinary team of scientists and technologists with combined expertise in next-generation sequencing, genomics, proteomics, and bioinformatics, and a common mission for unlocking the potential of single cell analysis at scale by eliminating barriers to discovery. ScaleBio is financed by leading life sciences tools investors ARCH Venture Partners, BNG and Tao Capital. ScaleBio has R&D facilities in San Diego and San Carlos, Calif.

### **Contacts**

For Media

Gwen Gordon

[gwen@gwengordonpr.com](mailto:gwen@gwengordonpr.com)

For General Inquiries

[info@scale.bio](mailto:info@scale.bio)